Apogee Therapeutics, Inc. - Common Stock — Financial Statements (NASDAQ:APGE) | MetaTrader

Open full chart Full chart

News

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE)

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Blackstone Backs Apogee With Up To $1.3 Billion

Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE)

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Why Delta, Starbucks and these other stocks were just added to a market-beating ‘fresh money’ list

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE)

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23

How Apogee, Up Almost 20%, Plans To Take On Rival Regeneron's Eczema Drug